CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss fo

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS

OF DECEMBER 31, 2023 AND JUNE 30, 2024

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

THE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

SIX MONTHS ENDED JUNE 30, 2023 AND 2024

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

THERAPEUTICS LIMITED AND SUBSIDIARIES

to the Unaudited Interim Condensed Consolidated Financial Statements

1 General Information

unaudited interim condensed consolidated financial statements are the unaudited interim financial statements of

CytoMed Therapeutics Limited (the "Company") and its subsidiaries (the "Group"), for the six months ended June

30, 2024 (the "Financial Statements").

The Company was incorporated in the Republic

of Singapore on March 9, 2018. The Company is a public limited company incorporated and domiciled in Singapore with registered office

situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered in Singapore and conducts its operations domestically

and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker symbol "GDTC" on April 14, 2023.

principal activities of the Group are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based

therapy and undertaking the research and development of immune cell and stem cell-based therapy. The Group conducts its primary

operations through its directly held wholly owned subsidiary that is incorporated and domiciled in Malaysia, namely CytoMed Therapeutics

(Malaysia) Sdn. Bhd., which is principally engaged in manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based

therapy and consultancy services and undertaking the research and development of immune cell and stem cell-based therapy for advancing

cellular immunotherapy to treat cancer.

principal activities of the subsidiaries of the Company are as follows:

Depository Sdn Bhd's principal activities were amended and updated after acquisition of the private blood bank licence.

2 Summary of significant accounting policies

The unaudited condensed interim consolidated financial statements for the six-month ended June 30, 2024 have been

prepared in accordance with IAS 34 Interim Financial Reporting.

unaudited interim consolidated financial statements do not include all the information and footnotes required by the International Financial Reporting Standards ("IFRS") for

complete financial statements. Certain information and note disclosures normally included in the annual financial statements prepared

in accordance with the IFRS have been condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company's

management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements

and include all adjustments, in normal recurring nature, as necessary for the fair statements of the Company's financial positions

as of June 30, 2024, and results of operations and cash flows for the six-month period ended June 30, 2024. The unaudited interim condensed

consolidated statements of financial positions as of December 31, 2023 has been derived from the audited financial statements at that

date but does not include all the information and footnotes required by the IFRS. Interim results of operations are not necessarily indicative

of the results expected for the full fiscal year or for any future period. These financial statements should be read in conjunction with

the audited consolidated financial statements as of and for the years ended December 31, 2023, 2022 and 2021, and related notes included

in the Company's audited consolidated financial statements.

accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group

has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning

on January 1, 2024. The adoption of these standards did not have any material effect on the unaudited interim condensed consolidated financial statements of the Group.

translations from Singapore dollars to U.S. dollars and from U.S. dollars to Singapore dollars in this Report are made at a rate of S$1.3552

to U.S.$1.00, the exchange rate in effect as of June 30, 2024 as set forth in the H.10 statistical release of the U.S. Board of Governors

of the Federal Reserve System.

liquidity risk management implies sufficient cash to finance the Group's and the Company's operations and development activities.

The Group manages the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group's

business operations and development activities. The Group's objective is to maintain a balance between continuing of funding and

flexibility through the use of borrowings.

April 18, 2023, the Company completed its initial public offering. In this offering, the Company issued 2,412,369 ordinary shares at

a price of U.S.$4.00 per share for aggregate gross proceeds of S$12,938,017. As of June 30, 2024, the Group has negative cash flow from

operating activities of S$1,155,878. The Group's working capital was positive S$7,349,681 as of June 30, 2024. At the same

time, the Group had S$6,471,648 in cash and bank balances, which is unrestricted as to withdrawal and use as of June 30, 2024. In view

of these circumstances, the management of the Group has given consideration to the future liquidity and performance of the Group and

its available sources of finance in assessing whether the Group will have sufficient financial resources to continue as a going concern,

at least, for the next twelve months from the date of this report.

3 Significant accounting judgements and estimates

preparation of the unaudited condensed interim consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported

amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period.

However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying

amount of the asset or liability affected in the future periods.

significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty

were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2023.

4 Segment information

information by operating segment is not presented as the Group's operating segment relates solely on the business of innate immune

cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based

5 Other operating income

6 Other losses/(gains) including fair value changes on financial instruments - net

Group measures the warrant liabilities at fair value using Black-Scholes option pricing model.

expenses include research personnel costs, depreciation of research equipment and laboratory consumables for research activities.

8 Employee benefits expenses

benefits are recognized as an expense, unless the cost qualifies to be capitalized as a development expenditure.

expenses arising from bank borrowings, loans and leases liabilities are presented as financing activities in the Unaudited Interim Condensed Consolidated Statements of Cash Flows.

11 Other receivables

of June 30, 2024, included in the deposits is a deposit of